

Press Release

Regulated information

DISCLOSURE OF ACQUISITION OF TREASURY SHARES

Waregem (Belgium) / Rotterdam (the Netherlands)¹, 22 August 2013 – Arseus discloses the information with respect to the acquisition of treasury shares required under Article 207 of the Royal Decree of 30 January 2001 implementing the Belgian Company Code.

Arseus today announces that during the period from 13 August to 21 August, it acquired 96,736 treasury shares on NYSE Euronext Brussels (through an intermediate, acting with a discretionary mandate).

Acquisition date	Number of shares	Average price	Lowest price	Highest price	Amount
13 August 2013	13,210	€ 21.0540	€ 20.99	€ 21.17	€ 278,123
14 August 2013	17,525	€ 21.2530	€ 21.10	€ 21.47	€ 372,459
15 August 2013	5,620	€ 21.2602	€ 21.18	€ 21.36	€ 119,482
16 August 2013	13,256	€ 21.3036	€ 21.07	€ 21.38	€ 282,401
19 August 2013	26,056	€ 21.3555	€ 21.12	€ 21.64	€ 556,439
20 August 2013	12,270	€ 21.6818	€ 21.43	€ 21.82	€ 266,036
21 August 2013	8,799	€ 21.7863	€ 21.58	€ 21.87	€ 191,698

In addition, Arseus acquired on 13 August 10,000 treasury shares via a block trade.

Acquisition date	Block	Price	Amount
13 August 2013	10,000	€ 21.06	€ 210,600

The Extraordinary Shareholders' Meeting held on 16 June 2009 renewed the authorisation of the Board of Directors to acquire treasury shares.

Prior to the transactions, Arseus held 631,378 treasury shares. As a result of the acquisition of 106,736 treasury shares, Arseus now holds 738,114 treasury shares.

¹ This press release was sent out by Arseus NV and Arseus BV.

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

For more information:

Constantijn van Rietschoten
Director of Corporate Communications
+31 88 33 11 222 (Office)
+31 6 53 69 15 85 (Mobile)
constantijn.van.rietschoten@arseus.com

Arseus profile

Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the healthcare sector in 30 countries worldwide. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical ICT-solutions. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.